Clinical trials: Alcoholic Liver Disease
Colorectal Neoplasms, Nonalcoholic Fatty Liver Disease
Study of the Association of Nonalcoholic Fatty Liver Disease With Colorectal Malignant Neoplasm
The aim of this sudy is to investigate the prevalence of colorectal cancer (CRC) in patients with nonalcoholic fatty liver disease (NAFLD) and evaluate whether NAFLD is a risk factor for CRC.
- Trial name
- NWC (NCT01657773)
- Testing
- Ultrasound examination and Colonoscopy examination
- Where
- China
- Volunteers
- 2,315 people, healthy volunteers welcome
- Sponsor
- Wenzhou Medical University
Non Alcoholic Steatohepatitis (NASH)
Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment
The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic…
- Trial name
- REGENERATE (NCT02548351)
- Testing
- Obeticholic Acid
- Where
- 346 sites in United States, Australia and 19 more
- Volunteers
- 2,477 people
- Sponsor
- Intercept Pharmaceuticals
Diabete Mellitus, T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)
Duodenal pulsENDO as an Early Treatment for Type 2 DM
This study is designed to evaluate the efficacy and safety of endoscopic duodenal re-cellularization therapy using pulsed electric field in individuals with in patients with a recent diagnosis of type 2 diabetes mellitus (T2DM).
- Trial name
- DREAM-1 (NCT07376486)
- Testing
- pulsENDO treatment
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Hepatic Steatosis
Quantitative US for Hepatic Steatosis
The purpose of this study is to investigate the diagnostic performance of quantitative ultrasound imaging parameter for the assessment of hepatic steatosis in patients with non-alcoholic fatty liver disease using magnetic…
- Trial name
- NCT04180631
- Testing
- Quantitative ultrasound imaging parameter (QUS)
- Where
- South Korea
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Cirrhosis
Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure
1. Further characterize the incidence of hyperfibrinolysis in cirrhotics 2. Correlate hyperfibrinolysis with 1. hepatitis C 2. alcoholic liver disease 3. the subset of a\&b with renal failure with and without dialysis 3.
- Trial name
- NCT02737345
- Testing
- Rotem
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Scott Allen
Obesity, Nonalcoholic Steatohepatitis
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects.
- Trial name
- NCT04561245
- Testing
- ALT-801
- Where
- Australia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Altimmune, Inc.
Liver Diseases, Liver Transplant; Complications
Prognostic Factors After Liver Transplantation
The study retrospectively reviewed the medical records of patients who received adult liver transplantation in Changhua Christian hospital from 2002 to 2019.
- Trial name
- NCT05018741
- Testing
- liver transplantation
- Volunteers
- 600 people
- Sponsor
- Changhua Christian Hospital
Healthy Participants
Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects
This study will evaluate safety, tolerability, and Pharmacokinetics (PK) of ID119031166M with the Exploration of Pharmacodynamic (PD) effects in Healthy Participants.
- Trial name
- NCT05604287
- Testing
- ID119031166M
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- IlDong Pharmaceutical Co Ltd
NASH - Nonalcoholic Steatohepatitis
Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)
This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.
- Trial name
- NCT03912532
- Testing
- NGM282
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 171 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Type2 Diabetes, NAFLD
Effects of VLCD and Bariatric Surgery in Patients With Type 2 Diabetes
The investigators are therefore interested to explore the effects of VLCD and different bariatric surgery procedures to changes in the physical deposition of fat in organs which regulate glucose metabolism (i.e.
- Conditions
- Type2 Diabetes, NAFLD, Obesity
- Trial name
- BARIATRICMRI (NCT05092399)
- Testing
- Bariatric Surgery
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- University of Nottingham
Alcoholic Hepatitis
N-Acetylcysteine in Severe Acute Alcoholic Hepatitis
Acute alcoholic hepatitis (AAH) is the most severe form of alcoholic liver disease (ALD) and is associated with a high risk of dying in the short term.
- Trial name
- NCT00962442
- Testing
- N-Acetylcysteine
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- Erasme University Hospital
Non Alcoholic Fatty Liver Disease
UDFF Performance Evaluation ((Ultrason Derived Fat Fraction)
The purpose of this study is to assess UDFF performance (compared to MRI)
- Trial name
- UDFF (NCT06080386)
- Testing
- UDFF
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Angers
Non-Alcoholic Fatty Liver Disease, Type2diabetes
Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD
This clinical trial will yield results about the therapeutic effect of combining pioglitazone with SGLT2i in people suffering from NAFLD associated with T2DM.
- Trial name
- NCT05942963
- Testing
- Empagliflozin 10 MG, Pioglitazone 15mg, Metformin
- Where
- Pakistan
- Volunteers
- 240 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Alcoholism, Alcohol Use Disorder
Impact of Integrating an Addiction Team on Post Liver Transplantation Survival for Alcohol-related Liver Disease and Its Complications.
Investigator seeks to determine wether integrating an addiction team into a liver transplantation unit improves the prognosis of patients with alcohol-related liver disease requiring liver transplantation.
- Conditions
- Alcoholism, Alcohol Use Disorder, Alcohol; Liver
- Trial name
- NCT04964687
- Testing
- Liver transplantation
- Where
- France
- Volunteers
- 616 people
- Sponsor
- University Hospital, Montpellier
Alcoholic Hepatitis
A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis
This clinical trial will test two new therapies for the treatment of alcoholic hepatitis. Patients who "respond" to the current standard of care therapy for alcoholic hepatitis(corticosteroid/prednisolone therapy) after 1 week of…
- Trial name
- NCT01903798
- Testing
- Mycophenolate mofetil, Prednisolone, Rilonacept
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Southern California Institute for Research and Education
Nonalcoholic Fatty Liver Disease
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
The purpose of this study is to evaluate the safety, tolerability, and drug levels of BMS-963272 compared to placebo in participants with nonalcoholic fatty liver disease (NAFLD) and high probability of advanced fibrosis.
- Trial name
- NCT04766476
- Testing
- BMS-963272
- Where
- 19 sites in United States
- Volunteers
- 9 people
- Sponsor
- Bristol-Myers Squibb
Non Alcoholic Fatty Liver Disease
The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver
The purpose of this study is to determine whether the dual therapy of the amino acid L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with non alcoholic fatty liver disease (NAFLD).
- Trial name
- NCT01956825
- Testing
- "slim water"
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Meir Medical Center
NAFLD, Diabetes
GLP-1 RA on Liver OMICS in MASLD
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue.
- Conditions
- NAFLD, Diabetes, Obesity
- Trial name
- OMICS in MASLD (NCT06982378)
- Testing
- GLP-1 receptor agonist
- Where
- United States
- Sponsor
- Medical College of Wisconsin
Non-Alcoholic Steatohepatitis (NASH)
Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)
Abdominal obesity and type-2 Diabetes are associated with chronic liver disorders resulting from the accumulation of fat in the liver (steatosis), which may progress towards hepatitis and possibly lead to cirrhosis and liver…
- Trial name
- NCT01694849
- Testing
- GFT505 80mg, GFT505 120mg
- Where
- 56 sites in United States, Belgium and 7 more
- Volunteers
- 275 people
- Sponsor
- Genfit
Hepatic Insufficiency
Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment
The primary objectives were: To determine the effects of steady state TPV co-administered with low dose RTV on steady state PegIFN and RBV in HIV negative subjects with mild hepatic impairment (scheme A) To determine the effects…
- Trial name
- NCT02259855
- Testing
- Tipranavir, Ritonavir, Pegylated interferon
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.